Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
VPRO Biogen Founder joins Viropro/Axxiom's board.
Ivor Royston, M.D., is an oncologist, researcher, scientist, entrepreneur and venture capitalist, recognized for his efforts to develop treatments for multiple disease targets and to fund biotechnology companies with promising science, technology or medicines. He speaks regularly at healthcare conferences and symposia throughout the United States, Europe and Asia.
One of Dr. Royston's most significant achievements may be his successful efforts to partner academic medical research with industry to take potential treatments more quickly from the benchtop to the bedside.
After co-founding the first biotechnology company in San Diego, California, he and his associates went on to form or invest in dozens of other biotechs, laying the foundation of the region's thriving biotech cluster, one of the three largest in the United States. As a venture capitalist, Dr. Royston invests in start-up companies that have promising technologies for treating and potentially curing diseases, including various forms of cancer.
VPRO Biogen Founder joins Viropro/Axxiom's board.
Ivor Royston, M.D., is an oncologist, researcher, scientist, entrepreneur and venture capitalist, recognized for his efforts to develop treatments for multiple disease targets and to fund biotechnology companies with promising science, technology or medicines. He speaks regularly at healthcare conferences and symposia throughout the United States, Europe and Asia.
One of Dr. Royston's most significant achievements may be his successful efforts to partner academic medical research with industry to take potential treatments more quickly from the benchtop to the bedside.
After co-founding the first biotechnology company in San Diego, California, he and his associates went on to form or invest in dozens of other biotechs, laying the foundation of the region's thriving biotech cluster, one of the three largest in the United States. As a venture capitalist, Dr. Royston invests in start-up companies that have promising technologies for treating and potentially curing diseases, including various forms of cancer.
Like to add that he was part of the team that founded Biogen
He's legit and yes, he has a good resume.
Patience on this one!
VPRO chart
No Reverse split on this one.
Touched intra-month highs briefly while the lows held strong on equal volume during a 60 day period.
Trend says upward: m&a, restructuring, and basic bullish stock chart developments.
$VPRO !!
Oversold.
Points of resistance to watch: .0068 .0079 .0093 .012 .015
Yeah. They will regret it!
SAN JOSE, Calif., Dec. 8, 2015 /PRNewswire/ -- Viropro, Inc. (OTCBB: VPRO), which has previously announced it will be changing its name to Axxiom, today announced that Ivor Royston, M.D. has agreed to join its Board of Directors effective immediately.
Dr. Royston is Founding Managing Member of Forward Ventures and a recognized leader in cancer research. He is widely recognized as a founding father of San Diego's biotech industry. In 1978, he co-founded Hybritech, Inc., San Diego's first biotechnology company, which was subsequently acquired by Eli Lilly & Co. In 1986, Dr. Royston co-founded IDEC Corporation, discoverer of Rituxan®, the first FDA-approved monoclonal antibody to treat B-cell lymphoma, prior to its merger with Biogen.
"We are delighted to have an executive and entrepreneur of Dr. Royston's stature join our Board," said Bruce Cohen, Chairman. "His decades of industry leadership and keen understanding of breakthroughs in cancer therapy will be truly transformative for Viropro as we continue our efforts to build a world-class company."
Because Dr. Royston is a renowned expert in Immuno-Oncology therapies, Viropro believes his value in helping exploit this product category could be significant, especially in light of Viropro's previously announced intention to acquire NovaRx. In addition Dr. Royston will support Viropro's ongoing pursuit of strategic partnerships with pharmaceutical companies and the acquisition of underappreciated assets. He will also play a pivotal role in recruiting senior executives for Viropro. Viropro's Board of Directors was unanimous in its approval of this nomination.
The effort to recruit Dr. Royston was spearheaded by Dr. Kenneth A. Sorensen, a member of Viropro's Board of Directors, who also directed the process leading to the proposed acquisition of NovaRx. "Dr. Royston's background is ideal both for Viropro's long term strategy of building a diversified portfolio of high value assets and the immediate task of completing the clinical development of the NovaRx cancer immunotherapy portfolio," said Dr. Sorensen.
Dr. Royston has also been instrumental in the formation, financing and development of numerous biotechnology companies including Applied Molecular Evolution (acquired by Eli Lilly); Corixa (acquired by GlaxoSmithKline); Dynavax; LigoCyte (acquired by Takeda); Morphotek (acquired by Eisai); Sequana Therapeutics (acquired by Celera); TargeGen (acquired by Sanofi); and Triangle Pharmaceuticals (acquired by Gilead). Dr. Royston currently serves on the Boards of Syndax, Biocept and Viracta. Dr. Royston received his B.A. (1967) and M.D. (1970) degrees from Johns Hopkins University and completed post-doctoral training in internal medicine and medical oncology at Stanford University. From 1990 until 2000, Dr. Royston was the President and Chief Executive Officer of Sidney Kimmel Cancer Center (formerly the San Diego Regional Cancer Center). From 1977 to 1990, he held various positions in academic medicine and cancer center at the University of California, San Diego (UCSD) School of Medicine. In 1994, he received the San Diego Entrepreneur of the Year Award. In 1997, President Clinton appointed Dr. Royston to a six-year term on the National Cancer Advisory Board. In 2006, Dr. Royston was inducted into the San Diego Entrepreneur Hall of Fame.
These small biotechs have small floats and move fast
$VPRO too
The fact that a new board member has joined means volumes to Viropro/Axxiom.
VPRO chart/merger/symbol change +++++++ low float breakout
Impatient traders
A symbol change and a confirmation shall be coming.
$VPRO
.01 is attainable. Can we spread the word on $VPRO?
Great details on the chart!
$VPRO
The simplest of bullish indicators is the moving average crossover:
http://stockcharts.com/h-sc/ui?s=VPRO
$VPRO
The bull flag pattern is found within an uptrend in a stock. This pattern is named for the resemblance of a flag on a pole. The bull flag is a continuation pattern which only slightly retraces.
Monarch Bay Securities is an investment banking firm that advises clients on mergers and acquisitions, capital raises and restructuring assignments in a wide array of industries and circumstances.
MBAYs recent arrival and its assignment on the L2, is now an interesting one!
$VPRO
Timber!! Let's get a real PE value here. Heading lower
An Ascending price channel, along with new MM support, is a good development, amongst other things.
$VPRO
VPRO nice chart!! small float. Shares locked. News coming
L2 looks nice. Good entry point for any new eyeballs
No shorting here. impatient trading. MBAY showed up to accumulate.
MBAY is a sponsor MM. Supplies a good bid to help lift microcaps.
The flippers are still around and they are taking losses and breaking even. Patience!!
VPRO low float.
MBAY is mostly a sponsor type MM. Big plus to see it on the L2 now!
No panic. Only patience with this one. Flippers get scared and go elsewhere... depends on your strategy!!
Lawsuits aren't completed in a matter of days. We cannot base this run on a telephone call in an ongoing proceeding.
VPRO low float. Good time to load! Look at the chart and pending news
Unsteady small flipping here. Patience!!
This .0065 area was a big break into resistance but .0072 is where a lot of volume has been before.
L2 is clean. Very nice!
VPRO bubbling news and breakout chart
Nice moves. Patience is paying